Avecho Biotechnology Ltd
Avecho Biotechnology Limited is an Australia-based biopharmaceutical company.
The business
Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from Vitamin E using proprietary and patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol, Veterinary Applications, among others. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
Small Caps Research
No research on Avecho Biotechnology Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise AVE based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Avecho Biotechnology advances CBD insomnia trial with Sandoz licensing deal and funding
Avecho Biotechnology (ASX: AVE) has received a maiden payment of approximately $4.7 million (US$3m) from international generic and biosimilar medicines specialist Sandoz. The payment forms part of a recently signed licensing agreement for the commercial rights to develop Avecho’s proprietary cannabidiol (CBD) product for insomnia treatment in Australia. Avecho has granted Sandoz exclusive commercial rights […]
Avecho Biotechnology signs exclusive licensing deal with Sandoz for CBD insomnia treatment
Avecho Biotechnology (ASX: AVE) has signed an exclusive 10-year development and licensing agreement with Swiss generic pharmaceuticals developer Sandoz Group to investigate the commercialisation of a cannabidiol (CBD) capsule for insomnia in Australia. The companies have identified a market in which nearly 9.5 million Australians experience symptoms of insomnia, with approximately 3.6 million of those […]
Avecho Biotechnology gains traction on commercialising TPM-enhanced oncology drugs
Long-term efforts by Avecho Biotechnology (ASX: AVE) to further the clinical and commercial potential of its TPM (tocopheryl phosphate mixture) enhanced products gained traction during the three months to end June. In May, the US Patent and Trade Marks Office allowed the company a new patent application covering an optimised manufacturing process for TPM. When […]
Avecho Biotechnology passes two-year stability point for CBD soft-gel capsule to treat insomnia
Pharmaceutical company Avecho Biotechnology (ASX: AVE) has passed a crucial two-year stability point milestone for its tocopheryl phosphate mixture (TPM)-enhanced cannabidiol (CBD) soft-gel capsule. Cannabinoids are susceptible to degradation from a number of external sources including oxygen, light, heat and acidity, which can often create challenges with long-term pharmaceutical stability. Specific cannabinoids (such as non-psychoactive […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.